Efficacy of Risankizumab in Patients With Active Psoriatic Arthritis

According to a study published in the Journal of Dermatological Treatment, risankizumab is efficacious across diverse patient demographics and psoriatic disease characteristics, consistently achieving key clinical outcomes.

Researchers investigated the efficacy of risankizumab in treating patients with active psoriatic arthritis (PsA) compared to placebo (KEEPsAKE 1 and KEEPsAKE 2 phase 3 trials). This post hoc integrated analysis assessed various efficacy outcomes at weeks 24 and 52, considering baseline demographics and clinical characteristics. Key outcomes included the percentage of patients achieving ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70), ≥90% improvement in Psoriasis Area and Severity Index scores, and reaching minimal disease activity or low disease activity status. The analysis involved 707 patients in the risankizumab group and 700 in the placebo group, with baseline characteristics being comparable.

At week 24, risankizumab showed significantly higher ACR20 response rates (46.3%–60.1%) compared to placebo (15.5%–36.2%), consistent across various subgroups. By week 52, patients initially receiving risankizumab maintained high ACR20 response rates (48.6%–75.8%), and those who switched from placebo to risankizumab also demonstrated marked improvement (43.7%–63.9%). Similar positive trends were observed for other efficacy measures, including stringent skin response and overall disease activity assessments.

Overall, risankizumab proved to be efficacious across diverse patient demographics and psoriatic disease characteristics over the 52-week period, consistently outperforming placebo in achieving key clinical outcomes.

Reference
Merola JF, Armstrong A, Khattri S, et al. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024;35(1):2342383. doi:10.1080/09546634.2024.2342383